Bristol Myers Squibb wraps up acquisition of MyoKardia

This article was originally published here

With the closing of the deal, MyoKardia now operates as a wholly-owned subsidiary of BMS. The deal provides BMS with MyoKardia’s mavacamten, which is a potential first-in-class cardiovascular

The post Bristol Myers Squibb wraps up acquisition of MyoKardia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply